TD Cowen raised the firm’s price target on Alignment Healthcare (ALHC) to $25 from $18.50 and keeps a Buy rating on the shares. The firm updated its model as thmpressed following a presentation at a recent investor conference, blessing FY26 consensus EBITDA falling within the initial guidance range, and 2026 MA enrollment is not expected to be materially higher than the +20% growth algo.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Alignment Healthcare price target raised to $21 from $18 at UBS
- Alignment Healthcare: Sustained Membership Growth and Expanding EBITDA Support Buy Rating
- Alignment Healthcare Reports Strong Medicare Advantage Membership Growth
- Alignment Healthcare reports 31% y/y membership growth as of January 1
- Alignment Healthcare price target raised to $30 from $20 at Piper Sandler